Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Exact Sciences Co. (NASDAQ:EXAS) has received an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and nineteen have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $70.26.

Several analysts have issued reports on the company. Royal Bank of Canada assumed coverage on Exact Sciences in a research note on Thursday, March 13th. They set a “sector perform” rating and a $52.00 price objective on the stock. Scotiabank lifted their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Piper Sandler dropped their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, Bank of America dropped their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th.

Exact Sciences Stock Down 3.0 %

Shares of NASDAQ:EXAS opened at $43.66 on Monday. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The firm has a market cap of $8.11 billion, a PE ratio of -7.84 and a beta of 1.25. The company has a fifty day simple moving average of $49.71 and a 200 day simple moving average of $57.75.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. On average, equities research analysts anticipate that Exact Sciences will post -0.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Exact Sciences

Institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC raised its position in shares of Exact Sciences by 9.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 39,135 shares of the medical research company’s stock worth $2,199,000 after buying an additional 3,434 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new stake in Exact Sciences in the fourth quarter worth approximately $3,767,000. Siemens Fonds Invest GmbH bought a new position in Exact Sciences during the 4th quarter valued at $215,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Exact Sciences during the 4th quarter valued at $8,949,000. Finally, Integrated Advisors Network LLC raised its stake in shares of Exact Sciences by 23.7% in the 4th quarter. Integrated Advisors Network LLC now owns 6,657 shares of the medical research company’s stock worth $374,000 after buying an additional 1,276 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.